Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Revlimid® as Consolidation Treatment of Residual Disease in Patients With Chronic Lymphocytic Leukemia (CLL)

NCT01600053 is registered in ClinicalTrials.gov with Thomas Kipps as lead sponsor.

NCT NCT01600053
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01600053 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Revlimid® as Consolidation Treatment of Residual Disease in Patients With Chronic Lymphocytic Leukemia (CLL)
Lead sponsor
Thomas Kipps
Phase
Phase 2
Overall status
Terminated
Start date
November 30, 2011
Completion date
May 31, 2014
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia